Advancements in Maternal RSV Vaccine: Protecting Newborns and Overcoming Obstacles

The Centers for Disease Control and Prevention (CDC) has recommended a new vaccine, Abrysvo, made by Pfizer, to protect newborns from respiratory syncytial virus (RSV), the leading cause of infant hospitalization in the U.S. The vaccine, given in late pregnancy, sends protective antibodies to the developing fetus. Clinical trials showed that the vaccine reduced the risk of RSV-related lung infections by 57% and severe infections by 76.5% in the first six months of life. The CDC advises administering the vaccine during RSV season, between weeks 32 and 36 of gestation. Infants can also receive antibody drugs after birth for protection against RSV.